Baxter CoSeal licensing PMA
This article was originally published in The Gray Sheet
Executive Summary
Regulatory responsibility for surgical sealant transfers to Baxter with approval. The submission required no data or inspections. Baxter licensed CoSeal manufacturing rights from Angiotech Pharmaceuticals in April (1"The Gray Sheet" April 28, 2003, In Brief)...
You may also be interested in...
Angiotech/Baxter
Manufacturing rights for Angiotech's CoSeal surgical sealant and Adhibit surgical anti-adhesive products are granted to Baxter under an April 21 agreement. The pact expands on the firms' Feb. 25 alliance giving Baxter exclusive worldwide distribution rights, except for Japan (1"The Gray Sheet" March 3, 2003, In Brief)...
Investors Go Beserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.